WO2004019934A1 - Utilisation de triptans en tant qu'agents antiviraux - Google Patents

Utilisation de triptans en tant qu'agents antiviraux Download PDF

Info

Publication number
WO2004019934A1
WO2004019934A1 PCT/EP2003/009435 EP0309435W WO2004019934A1 WO 2004019934 A1 WO2004019934 A1 WO 2004019934A1 EP 0309435 W EP0309435 W EP 0309435W WO 2004019934 A1 WO2004019934 A1 WO 2004019934A1
Authority
WO
WIPO (PCT)
Prior art keywords
triptans
affections
triptan
patients
symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/009435
Other languages
English (en)
Inventor
Antonio Cassar Scalia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU2003273803A priority Critical patent/AU2003273803A1/en
Publication of WO2004019934A1 publication Critical patent/WO2004019934A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Definitions

  • Triptans form a class of drugs obtained from indole.
  • Triptans are drugs widely used to treat migraines and a certain number of them are cited in the literature and indicated for this type of therapy, For example in Martindale (The complete drug reference, thirty-second edition, pages 443-452) the following triptans are quoted: almotriptan, elitriptan, frovatriptan, naratriptan hydrochloride, rizatriptan benzoate, sumatriptan succinate and zolmitriptan.
  • triptan since the first synthesized and marketed triptan (sumatriptan), have been targeted at improving efficacy and decreasing side effects, always within the sphere of treating migraines.
  • the activity of triptans against migraines is attributed to the fact that they function as agonists at the 5HT-ID receptors and that their action on the similar 5HT*ID - receptors present in cranial circulation inhibits the release of neuropeptides (CGRP and substance P) by perivascular trigeminal sensory neurons (E. Seaber et al. British J. of Clinical Pharmacology, 1997, 43, pages 579-587). No suggestion has ever been made for therapeutic treatments of affections other than migraines. Summary
  • the present invention relates to a new use of triptans as active ingredients for the preparation of pharmaceutical compositions suitable to treat viral affections.
  • the invention also relates to pharmaceutical compositions containing as active ingredient triptan mixed with pharmaceutically acceptable excipients or diluents, suitable to treat viral affections.
  • the invention relates to a therapeutic method for treating viral affections comprising the administration of an efficacious dose of a triptan.
  • triptans described in the examples were zolmitriptan, rizatriptan and sumatriptan, taken orally in doses ranging from 2.5 to 50 mg/day. In all the cases treated the triptans were found to be extremely efficacious against viral pathologies. This efficacy, depending on the period in which the drugs were taken, ranged from simple improvement of the symptoms to total remission, and even true abortive forms of the infection, in particular it was noted that when triptans were administered at the onset of the first symptoms of the infection, they were capable of totally blocking evolution of the disease.
  • triptans when triptans were taken when the affection was already in progress, they considerably reduced the symptoms and drastically decreased the normal evolution and febrile period.
  • the extent of the anti-infective action of these drugs proved to be correlated to the evolutional phase of the disease. The earlier they were administered the more effective and rapid their action was, to the extent that taking minimum but repeated doses simultaneously to the onset of the first symptoms was able to totally and rapidly resolve the symptoms of the various viral affections. All triptans have proved to be extremely efficacious in the treatment of viral affections. Nonetheless some differences in efficacy were found, for example: sumatriptan ⁇ rizatriptan ⁇ zolmitriptan.
  • triptans may be used successfully to prepare pharmaceutical compositions suitable to treat viral affections, mixed with acceptable pharmaceutical excipients.
  • Said pharmaceutical compositions may each contain from 1.25 to 50 mg of triptan (depending on the triptan used).
  • lactose, microcrystalline cellulose, mannitol, sodium starch glycolate, corn starch, aspartame, crospovidone, polyethyleneglycol, magnesium stearate, colloidal silica and ferric oxide may be employed as excipients.
  • the present invention also relates to a therapeutic method for treating viral affections comprising the oral administration of a dose ranging from 2.5 to 100 mg of triptan per day.
  • triptans are also capable of rapidly and radically resolving the infective episode.
  • an antiviral action that could be implemented at the level of cellular receptors for viruses or through a mechanism that prevents viruses from being adsorbed and penetrating inside the cell or through a mechanism that impedes the capacity of virions that have entered the cell to induce the genome of the cell to allow their replication. It is clear that this is a hypothesis that would require a great deal of research in order to be verified.
  • the following examples of antiviral efficacy in patients treated with triptans are provided for the purpose of illustrating the invention.
  • Example 7 Five patients with mononucleosis infection from cytomegalovirus diagnosed from the clinical-epidemiological symptoms confirmed by the presence of specific IgM antibodies in the blood, were treated with 2.5 mg of zolmitriptan (ZOMIG ®) per day divided into two 1.25 mg doses.
  • ZOMIG ® zolmitriptan

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne l'utilisation de triptans dans la préparation de compositions pharmaceutiques adaptées au traitement d'infections virales.
PCT/EP2003/009435 2002-08-28 2003-08-26 Utilisation de triptans en tant qu'agents antiviraux Ceased WO2004019934A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003273803A AU2003273803A1 (en) 2002-08-28 2003-08-26 Use of triptans as antiviral agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2002A001860 2002-08-28
IT001860A ITMI20021860A1 (it) 2002-08-28 2002-08-28 Impiego dei triptani come agenti antivirali.

Publications (1)

Publication Number Publication Date
WO2004019934A1 true WO2004019934A1 (fr) 2004-03-11

Family

ID=31972200

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/009435 Ceased WO2004019934A1 (fr) 2002-08-28 2003-08-26 Utilisation de triptans en tant qu'agents antiviraux

Country Status (3)

Country Link
AU (1) AU2003273803A1 (fr)
IT (1) ITMI20021860A1 (fr)
WO (1) WO2004019934A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102219725A (zh) * 2010-04-16 2011-10-19 中国科学院上海药物研究所 苯并杂环类化合物及其制备方法和用途
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8809265B2 (en) 2011-10-21 2014-08-19 Abbvie Inc. Methods for treating HCV
US8853176B2 (en) 2011-10-21 2014-10-07 Abbvie Inc. Methods for treating HCV
WO2017189978A1 (fr) 2016-04-28 2017-11-02 Emory University Compositions thérapeutiques à base de nucléotides et nucléosides contenant un alcyne et utilisations associées
US20220305088A1 (en) * 2017-06-19 2022-09-29 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996001107A1 (fr) * 1994-07-06 1996-01-18 Bo Arne Hofmann Emploi d'agents pharmaceutiques retablissant, ameliorant ou traitant la deficience immunitaire et notamment ameliorant ou traitant certains troubles immunitaires lies a des infections par le vih

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996001107A1 (fr) * 1994-07-06 1996-01-18 Bo Arne Hofmann Emploi d'agents pharmaceutiques retablissant, ameliorant ou traitant la deficience immunitaire et notamment ameliorant ou traitant certains troubles immunitaires lies a des infections par le vih

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AFZELIUS P ET AL: "Sumatriptan increases the proliferation of peripheral blood mononuclear cells from HIV- infected individuals and healthy blood donors in vitro.", APMIS, (2000 JAN) 108 (1) 74-8., XP009023377 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102219725B (zh) * 2010-04-16 2013-10-09 中国科学院上海药物研究所 苯并杂环类化合物及其制备方法和用途
CN102219725A (zh) * 2010-04-16 2011-10-19 中国科学院上海药物研究所 苯并杂环类化合物及其制备方法和用途
US8809265B2 (en) 2011-10-21 2014-08-19 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8680106B2 (en) 2011-10-21 2014-03-25 AbbVic Inc. Methods for treating HCV
US8685984B2 (en) 2011-10-21 2014-04-01 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8853176B2 (en) 2011-10-21 2014-10-07 Abbvie Inc. Methods for treating HCV
US8969357B2 (en) 2011-10-21 2015-03-03 Abbvie Inc. Methods for treating HCV
US8993578B2 (en) 2011-10-21 2015-03-31 Abbvie Inc. Methods for treating HCV
US9452194B2 (en) 2011-10-21 2016-09-27 Abbvie Inc. Methods for treating HCV
WO2017189978A1 (fr) 2016-04-28 2017-11-02 Emory University Compositions thérapeutiques à base de nucléotides et nucléosides contenant un alcyne et utilisations associées
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US20220305088A1 (en) * 2017-06-19 2022-09-29 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection

Also Published As

Publication number Publication date
ITMI20021860A1 (it) 2004-02-29
AU2003273803A1 (en) 2004-03-19

Similar Documents

Publication Publication Date Title
RU2221563C2 (ru) Фармацевтическая композиция для лечения болезни паркинсона и синдромов паркинсона, способ ее получения, способ лечения болезни паркинсона и синдромов паркинсона
JP2022517433A5 (fr)
CN1440283A (zh) 有机化合物的联合形式
JP2011190279A (ja) 線維筋痛症及び関連症状の治療におけるフルピルチン
ES2210490T3 (es) Uso de valaciclovir para la fabricacion de un medicamento para el tratamiento del herpes genital por una unica administracion diaria.
WO2005004915A2 (fr) Compositions contenant meloxicam
WO2005094832A1 (fr) Compositions contenant du meloxicame
AU2003296647A1 (en) Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors
CA2522971A1 (fr) Methode pour ameliorer la diurese chez des personnes a fonction renale alteree
JP5386477B2 (ja) 脊髄損傷を治療するための４−シクロプロピルメトキシ−ｎ−（３，５−ジクロロ−１−オキシドピリジン−４−イル）−５−（メトキシ）ピリジン−２−カルボキサミドの使用
AU666992B2 (en) Pharmaceutical composition for preventing or treating arteriosclerosis
CN113329749A (zh) 用于治疗葡萄膜黑色素瘤的联合疗法
JP2023533662A5 (fr)
EP2146714B1 (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson
KR20230050363A (ko) 질환의 치료에 있어서 btk 저해제의 용도
US20080319087A1 (en) Use of Ambroxol for the Treatment of Rhinovirus Infections
US20020099059A1 (en) Combination therapy for the treatment of migraine
JP2003523385A5 (fr)
Davey New antiviral and antifungal drugs
JP5386476B2 (ja) 頭蓋外傷の治療のための４−シクロプロピルメトキシ−ｎ−（３，５−ジクロロ−１−オキシド−４−ピリジン−４−イル）−５−（メトキシ）ピリジン−２−カルボキサミドの使用
ES2352216T3 (es) Combinaciones farmacéuticas que contienen lamivudina, estavudina y nevirapina.
JPH0251405B2 (fr)
HU226374B1 (en) Pharmaceutical combination of a bradykinin antagonist and an antiviral agent
CN121622909A (zh) 用于预防、治疗或减轻尿酸代谢障碍的药物组合物及用途
WO2025181153A1 (fr) Utilisation d'inhibiteurs d'atr en combinaison avec des inhibiteurs de pi3k alpha

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP